Isamu Okamoto

2015

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Yonesaka, K., Kudo, K., Nishida, S., Takahama, T., Iwasa, T., Yoshida, T., Tanaka, K., Takeda, M., Kaneda, H., Okamoto, I., Nishio, K. & Nakagawa, K., Jan 1 2015, In : Oncotarget. 6, 32, p. 33602-33611 10 p.

Research output: Contribution to journal › Article

Neuregulin-1

Non-Small Cell Lung Carcinoma

Protein-Tyrosine Kinases

Ligands

Phosphorylation

27 Citations (Scopus)

Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: A phase 1 study in japanese patients with previously treated non-small-cell lung cancer

Okamoto, I., Miyazaki, M., Takeda, M., Terashima, M., Azuma, K., Hayashi, H., Kaneda, H., Kurata, T., Tsurutani, J., Seto, T., Hirai, F., Konishi, K., Sarashina, A., Yagi, N., Kaiser, R. & Nakagawa, K., Feb 6 2015, In : Journal of Thoracic Oncology. 10, 2, p. 346-352 7 p.

Research output: Contribution to journal › Article

docetaxel

Body Surface Area

Non-Small Cell Lung Carcinoma

Maximum Tolerated Dose

nintedanib

2014

32 Citations (Scopus)

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

Li, H., Takayama, K., Wang, S., Shiraishi, Y., Gotanda, K., Harada, T., Furuyama, K., Iwama, E., Ieiri, I., Okamoto, I. & Nakanishi, Y., Oct 9 2014, In : Cancer chemotherapy and pharmacology. 74, 6, p. 1297-1305 9 p.

Research output: Contribution to journal › Article

Heterografts

Non-Small Cell Lung Carcinoma

Vascular Endothelial Growth Factor A

Cells

Tumors

1 Citation (Scopus)

A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer

Okamoto, K., Okamoto, I., Takeda, M., Kobayashi, S., Takeda, K., Nakamatsu, K., Nishimura, Y. & Nakagawa, K., Aug 2014, In : Japanese journal of clinical oncology. 44, 8, p. 743-748 6 p., hyu071.

Research output: Contribution to journal › Article

Small Cell Lung Carcinoma

Etoposide

Cisplatin

Radiotherapy

Thorax

318 Citations (Scopus)

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., Hoshino, T., Nakanishi, Y. & Okamoto, I., Oct 1 2014, In : Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 25, 10, p. 1935-1940 6 p.

Research output: Contribution to journal › Article

erbB-1 Genes

Non-Small Cell Lung Carcinoma

Ligands

Mutation

Cell Line

16 Citations (Scopus)

Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement

Fujiwara, A., Higashiyama, M., Kanou, T., Tokunaga, T., Okami, J., Kodama, K., Nishino, K., Tomita, Y. & Okamoto, I., Feb 1 2014, In : Lung Cancer. 83, 2, p. 302-304 3 p.

Research output: Contribution to journal › Article

Gene Rearrangement

Non-Small Cell Lung Carcinoma

Neoplasm Metastasis

Fluorescence In Situ Hybridization

anaplastic lymphoma kinase

53 Citations (Scopus)

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance

Park, K. S., Raffeld, M., Moon, Y. W., Xi, L., Bianco, C., Pham, T., Lee, L. C., Mitsudomi, T., Yatabe, Y., Okamoto, I., Subramaniam, D., Mok, T., Rosell, R., Luo, J., Salomon, D. S., Wang, Y. & Giaccone, G., Jul 1 2014, In : Journal of Clinical Investigation. 124, 7, p. 3003-3015 13 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

MicroRNAs

Epithelial-Mesenchymal Transition

Protein-Tyrosine Kinases

Mutation

3 Citations (Scopus)

Current status and future perspectives of cooperative study groups for lung cancer in Japan

Kawano, Y., Okamoto, I., Fukuda, H., Ohe, Y., Nakamura, S., Nakagawa, K., Hotta, K., Kiura, K., Takiguchi, Y., Saka, H., Okamoto, H., Takayama, K., Semba, H., Kobayashi, K., Kenmotsu, H., Tsuboi, M., Yamamoto, N., Nukiwa, T. & Nakanishi, Y., Nov 1 2014, In : Respiratory Investigation. 52, 6, p. 339-347 9 p.

Research output: Contribution to journal › Review article

Lung Neoplasms

Japan

Clinical Trials

Research Personnel

Therapeutics

18 Citations (Scopus)

Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement

Hayashi, H., Okamoto, I., Tanizaki, J., Tanaka, K., Okuda, T., Kato, A., Nishimura, Y. & Nakagawa, K., Jan 1 2014, In : Journal of Clinical Oncology. 32, 36, p. e122-e124 A31.

Research output: Contribution to journal › Article

Gene Rearrangement

Receptor Protein-Tyrosine Kinases

Non-Small Cell Lung Carcinoma

Brain Neoplasms

Cysts

31 Citations (Scopus)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Iwama, E., Okamoto, I., Harada, T., Takayama, K. & Nakanishi, Y., Mar 5 2014, In : OncoTargets and Therapy. 7, p. 375-385 11 p.

Research output: Contribution to journal › Review article

Lung Neoplasms

Non-Small Cell Lung Carcinoma

anaplastic lymphoma kinase

United States Food and Drug Administration

Oncogenes

371 Citations (Scopus)

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study

Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., Nagase, S., Okamoto, I., Yamanaka, T., Tajima, K., Harada, R., Fukuoka, M. & Yamamoto, N., Oct 1 2014, In : The Lancet Oncology. 15, 11, p. 1236-1244 9 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Mutation

Therapeutics

Disease-Free Survival

Bevacizumab

18 Citations (Scopus)

Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: Results of a West Japan Oncology Group study

Okamoto, I., Sakai, K., Morita, S., Yoshioka, H., Kaneda, H., Takeda, K., Hirashima, T., Kogure, Y., Kimura, T., Takahashi, T., Atagi, S., Seto, T., Sawa, T., Yamamoto, M., Satouchi, M., Okuno, M., Nagase, S., Takayama, K., Tomii, K., Maeda, T. & 8 others, Oizumi, S., Fujii, S., Akashi, Y., Nishino, K., Ebi, N., Nakagawa, K., Nakanishi, Y. & Nishio, K., Apr 2014, In : Oncotarget. 5, 8, p. 2293-2304 12 p.

Research output: Contribution to journal › Article

Carboplatin

Paclitaxel

Non-Small Cell Lung Carcinoma

Japan

Mutation

19 Citations (Scopus)

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer

Hirsh, V., Okamoto, I., Hon, J. K., Page, R. D., Orsini, J., Sakai, H., Zhang, H., Renschler, M. F. & Socinski, M. A., Jan 1 2014, In : Journal of Thoracic Oncology. 9, 1, p. 83-90 8 p.

Research output: Contribution to journal › Article

Carboplatin

Paclitaxel

Non-Small Cell Lung Carcinoma

Peripheral Nervous System Diseases

Physicians

3 Citations (Scopus)

Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer

Naito, T., Seto, T., Takeda, K., Goto, K., Okamoto, I., Nakagawa, K., Ohba, T., Murakami, H., Takahashi, T., Yamanaka, T. & Yamamoto, N., Dec 1 2014, In : Lung Cancer. 86, 3, p. 339-343 5 p.

Research output: Contribution to journal › Article

Phase II Clinical Trials

Leucovorin

Non-Small Cell Lung Carcinoma

Disease-Free Survival

Pneumatosis Cystoides Intestinalis

14 Citations (Scopus)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group

Murakami, H., Yamanaka, T., Seto, T., Sugio, K., Okamoto, I., Sawa, T., Hirashima, T., Takeda, K., Atagi, S., Fukuoka, M., Nakanishi, Y., Nakagawa, K. & Yamamoto, N., Aug 2014, In : Cancer Science. 105, 8, p. 989-995 7 p.

Research output: Contribution to journal › Article

zoledronic acid

docetaxel

Non-Small Cell Lung Carcinoma

Japan

Confidence Intervals

35 Citations (Scopus)

Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib

Takeda, M., Okamoto, I. & Nakagawa, K., Feb 1 2014, In : Journal of Thoracic Oncology. 9, 2, p. 200-204 5 p.

Research output: Contribution to journal › Article

erbB-1 Genes

Non-Small Cell Lung Carcinoma

Mutation

Survival

Protein-Tyrosine Kinases

46 Citations (Scopus)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

Kawakami, H., Okamoto, I., Yonesaka, K., Okamoto, K., Shibata, K., Shinkai, Y., Sakamoto, H., Kitano, M., Tamura, T., Nishio, K. & Nakagawa, K., Jan 1 2014, In : Oncotarget. 5, 23, p. 11847-11856 10 p.

Research output: Contribution to journal › Article

Neuregulin-1

Anti-Idiotypic Antibodies

Colorectal Neoplasms

Phosphorylation

Cetuximab

70 Citations (Scopus)

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer

Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J., Rawal, B., Fisher, K. J., Chen, A. Y., Kitano, M., Morita, Y., Yamaguchi, H., Shibata, K., Okabe, T., Okamoto, I., Nakagawa, K. & Haura, E. B., Aug 1 2014, In : Clinical Cancer Research. 20, 15, p. 4059-4074 16 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Protein-Tyrosine Kinases

Tyrosine

src-Family Kinases

Phosphorylation

2013

14 Citations (Scopus)

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors

Okamoto, W., Yoshino, T., Takahashi, T., Okamoto, I., Ueda, S., Tsuya, A., Boku, N., Nishio, K., Fukuoka, M., Yamamoto, N. & Nakagawa, K., Nov 1 2013, In : Cancer chemotherapy and pharmacology. 72, 5, p. 1063-1071 9 p.

Research output: Contribution to journal › Article

Pharmacodynamics

Pharmacokinetics

Epidermal Growth Factor Receptor

Toxicity

Tumors

1 Citation (Scopus)

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Tsuya, A., Kurata, T., Tamiya, A., Okamoto, I., Ueda, S., Sakai, D., Sugimoto, N., Matsumoto, K., Goto, I., Yamamoto, N., Fukuoka, M. & Nakagawa, K., Dec 1 2013, In : Investigational New Drugs. 31, 6, p. 1568-1572 5 p.

Research output: Contribution to journal › Article

Cisplatin

Carcinoma

Combination Drug Therapy

Appointments and Schedules

Febrile Neutropenia

1 Citation (Scopus)

A phase i study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer

Hasegawa, Y., Okamoto, I., Takezawa, K., Miyazaki, M., Tsurutani, J., Yonesaka, K., Morinaga, R., Tsuya, A., Terashima, M., Kudoh, T., Azuma, K., Kurata, T., Nishikawa, T., Fukuoka, M., Nishimura, Y. & Nakagawa, K., Jun 1 2013, In : Investigational New Drugs. 31, 3, p. 599-604 6 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Radiotherapy

Thorax

Stomatitis

Pneumonia

1 Citation (Scopus)

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer

Okamoto, K., Okamoto, I., Miyazaki, M., Tanaka, K., Kaneda, H. & Nakagawa, K., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1364-1366 3 p.

Research output: Contribution to journal › Article

Bronchoscopy

Non-Small Cell Lung Carcinoma

Hemorrhage

Lung

Hemoptysis

61 Citations (Scopus)

Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement

Takeda, M., Okamoto, I. & Nakagawa, K., May 1 2013, In : Journal of Thoracic Oncology. 8, 5, p. 654-657 4 p.

Research output: Contribution to journal › Article

Lung Neoplasms

Central Nervous System

Radiotherapy

Non-Small Cell Lung Carcinoma

Disease Progression

13 Citations (Scopus)

Clinical response to crizotinib retreatment after acquisition of drug resistance

Matsuoka, H., Kurata, T., Okamoto, I., Kaneda, H., Tanaka, K. & Nakagawa, K., Jul 1 2013, In : Journal of Clinical Oncology. 31, 19

Research output: Contribution to journal › Article

Fusion Oncogene Proteins

Serine Endopeptidases

Neoplasm Drug Resistance

Drug Administration Schedule

Antineoplastic Combined Chemotherapy Protocols

40 Citations (Scopus)

Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study

Yoshioka, H., Okamoto, I., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Atagi, S., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Nakanishi, Y. & Nakagawa, K., May 1 2013, In : Annals of Oncology. 24, 5, p. 1326-1331 6 p., mds629.

Research output: Contribution to journal › Article

Carboplatin

Non-Small Cell Lung Carcinoma

Histology

Japan

Safety

26 Citations (Scopus)

Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer

Satouchi, M., Okamoto, I., Sakai, H., Yamamoto, N., Ichinose, Y., Ohmatsu, H., Nogami, N., Takeda, K., Mitsudomi, T., Kasahara, K. & Negoro, S., Jul 1 2013, In : Lung Cancer. 81, 1, p. 97-101 5 p.

Research output: Contribution to journal › Article

Carboplatin

Non-Small Cell Lung Carcinoma

Safety

Paclitaxel

Thrombocytopenia

1 Citation (Scopus)

Erratum: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer (Investigational New Drugs (DOI 10.1007/s10637-013-9941-z))

Okamoto, I., Aoe, K., Kato, T., Hosomi, Y., Yokoyama, A., Imamura, F., Kiura, K., Hirashima, T., Nishio, M., Nogami, N., Okamoto, H., Saka, H., Yamamoto, N., Yoshizuka, N., Sekiguchi, R., Kiyosawa, K., Nakagawa, K. & Tamura, T., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1395-1396 2 p.

Research output: Contribution to journal › Comment/debate

Pemetrexed

Investigational Drugs

Carboplatin

Non-Small Cell Lung Carcinoma

Therapeutics

26 Citations (Scopus)

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of west Japan oncology group (WJOG) study 3906L

Kogure, Y., Ando, M., Saka, H., Chiba, Y., Yamamoto, N., Asami, K., Hirashima, T., Seto, T., Nagase, S., Otsuka, K., Yanagihara, K., Takeda, K., Okamoto, I., Aoki, T., Takayama, K., Yamasaki, M., Kudoh, S., Katakami, N., Miyazaki, M. & Nakagawa, K., Jun 2013, In : Journal of Thoracic Oncology. 8, 6, p. 753-758 6 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Histology

Japan

Smoking

Adenocarcinoma

19 Citations (Scopus)

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma

Kawakami, H., Okamoto, I., Terao, K., Sakai, K., Suzuki, M., Ueda, S., Tanaka, K., Kuwata, K., Morita, Y., Ono, K., Nishio, K., Nishimura, Y., Doi, K. & Nakagawa, K., Dec 2013, In : Cancer Medicine. 2, 6, p. 933-941 9 p.

Research output: Contribution to journal › Article

Squamous Cell Carcinoma

DNA

p16 Genes

Methylation

Cisplatin

65 Citations (Scopus)

MET amplification as a potential therapeutic target in gastric cancer

Kawakami, H., Okamoto, I., Arao, T., Okamoto, W., Matsumoto, K., Taniguchi, H., Kuwata, K., Yamaguchi, H., Nishio, K., Nakagawa, K. & Yamada, Y., 2013, In : Oncotarget. 4, 1, p. 9-17 9 p.

Research output: Contribution to journal › Article

Stomach Neoplasms

Protein-Tyrosine Kinases

Therapeutics

Polymerase Chain Reaction

Gene Dosage

15 Citations (Scopus)

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Kaneda, H., Yoshida, T. & Okamoto, I., May 29 2013, In : Cancer Management and Research. 5, 1, p. 91-101 11 p.

Research output: Contribution to journal › Review article

Non-Small Cell Lung Carcinoma

Epidermal Growth Factor Receptor

Protein-Tyrosine Kinases

Mutation

erbB-1 Genes

26 Citations (Scopus)

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer

Okamoto, I., Aoe, K., Kato, T., Hosomi, Y., Yokoyama, A., Imamura, F., Kiura, K., Hirashima, T., Nishio, M., Nogami, N., Okamoto, H., Saka, H., Yamamoto, N., Yoshizuka, N., Sekiguchi, R., Kiyosawa, K., Nakagawa, K. & Tamura, T., Jan 1 2013, In : Investigational New Drugs. 31, 5, p. 1275-1282 8 p.

Research output: Contribution to journal › Article

Pemetrexed

Carboplatin

Non-Small Cell Lung Carcinoma

Epidermal Growth Factor Receptor

Therapeutics

31 Citations (Scopus)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms

Li, J., Bennett, K., Stukalov, A., Fang, B., Zhang, G., Yoshida, T., Okamoto, I., Kim, J. Y., Song, L., Bai, Y., Qian, X., Rawal, B., Schell, M., Grebien, F., Winter, G., Rix, U., Eschrich, S., Colinge, J., Koomen, J., Superti-Furga, G. & 1 others, Haura, E. B., Nov 5 2013, In : Molecular Systems Biology. 9, 705.

Research output: Contribution to journal › Article

Growth Factors

resistance mechanisms

Vulnerability

Epidermal Growth Factor Receptor

Receptor

8 Citations (Scopus)

Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer

Urata, Y., Okamoto, I., Takeda, M., Hattori, Y., Okuno, K., Shimada, T., Kurata, T., Kaneda, H., Miyazaki, M., Terashima, M., Tanaka, K., Morita, S., Nakagawa, K., Negoro, S. & Satouchi, M., Jun 15 2013, In : Cancer. 119, 12, p. 2275-2281 7 p.

Research output: Contribution to journal › Article

Carboplatin

Non-Small Cell Lung Carcinoma

Maintenance

Drug Therapy

Disease Progression

5 Citations (Scopus)

Phase i and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Kiyota, H., Okamoto, I., Takeda, M., Daga, H., Naito, T., Miyazaki, M., Okada, H., Hayashi, H., Tanaka, K., Terashima, M., Azuma, K., Murakami, H., Takeda, K., Yamamoto, N. & Nakagawa, K., Apr 1 2013, In : Cancer Chemotherapy and Pharmacology. 71, 4, p. 859-865 7 p.

Research output: Contribution to journal › Article

Pharmacokinetics

Therapeutics

Chemotherapy

Aspartate Aminotransferases

Disease-Free Survival

8 Citations (Scopus)

Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

Hayashi, H., Tsurutani, J., Satoh, T., Masuda, N., Okamoto, W., Morinaga, R., Terashima, M., Miyazaki, M., Okamoto, I., Nishida, Y., Tominaga, S., Tokunaga, Y., Yamaguchi, M., Sakamoto, J., Nakayama, T. & Nakagawa, K., Apr 1 2013, In : Breast Cancer. 20, 2, p. 131-136 6 p.

Research output: Contribution to journal › Article

irinotecan

Breast Neoplasms

Anthracyclines

Taxoids

Topoisomerase I Inhibitors

1 Citation (Scopus)

Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer

Hayashi, H., Okamoto, I., Ueda, S., Tanaka, K., Okamoto, K., Kawakami, H., Nishina, S., Takeda, M., Fujisaka, Y., Satoh, T., Terao, K., Nishimura, Y., Doi, K. & Nakagawa, K., Dec 1 2013, In : Anticancer research. 33, 12, p. 5699-5706 8 p.

Research output: Contribution to journal › Article

Head and Neck Neoplasms

Pharmacokinetics

Neutropenia

Endpoint Determination

nedaplatin

12 Citations (Scopus)

Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

Kawakami, H., Okamoto, I., Hayashi, H., Taguri, M., Morita, S. & Nakagawa, K., Sep 1 2013, In : European Journal of Cancer. 49, 14, p. 3003-3009 7 p.

Research output: Contribution to journal › Article

Stomach Neoplasms

Drug Therapy

Survival

Disease-Free Survival

19 Citations (Scopus)

Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy

Hayashi, H., Okamoto, I., Taguri, M., Morita, S. & Nakagawa, K., Jul 15 2013, In : Clinical Lung Cancer. 14, 3, p. 261-266 6 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Drug Therapy

Survival

Disease-Free Survival

Therapeutics

242 Citations (Scopus)

Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial

Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., Hamamoto, Y., Morita, S., Okamoto, I., Boku, N. & Hyodo, I., Dec 10 2013, In : Journal of Clinical Oncology. 31, 35, p. 4438-4444 7 p.

Research output: Contribution to journal › Article

irinotecan

Paclitaxel

Combination Drug Therapy

Platinum

Stomach Neoplasms

43 Citations (Scopus)

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer

Kaneda, H., Okamoto, I. & Nakagawa, K., Apr 1 2013, In : Journal of Thoracic Oncology. 8, 4, p. e32-e33

Research output: Contribution to journal › Article

Pyrazoles

Pyridines

Bone Neoplasms

X Ray Computed Tomography

Gene Rearrangement

49 Citations (Scopus)

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Yamamoto, N., Zhang, H. & Renschler, M. F., Sep 1 2013, In : Annals of Oncology. 24, 9, p. 2390-2396 7 p., mdt235.

Research output: Contribution to journal › Article

Carboplatin

Non-Small Cell Lung Carcinoma

Histology

Safety

Paclitaxel

82 Citations (Scopus)

Safety and efficacy of weekly nab ^® -paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Socinski, M. A., Langer, C. J., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., Orsini, J., Zhang, H. & Renschler, M. F., Feb 1 2013, In : Annals of Oncology. 24, 2, p. 314-321 8 p., mds461.

Research output: Contribution to journal › Article

Carboplatin

Non-Small Cell Lung Carcinoma

Safety

Disease-Free Survival

Paclitaxel

34 Citations (Scopus)

Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer

Tamiya, A., Okamoto, I., Miyazaki, M., Shimizu, S., Kitaichi, M. & Nakagawa, K., Jan 1 2013, In : Journal of Clinical Oncology. 31, 1

Research output: Contribution to journal › Article

Fusion Oncogene Proteins

Pyrazoles

Pyridines

X Ray Computed Tomography

Fatal Outcome

13 Citations (Scopus)

Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs

Ogi, S., Fujita, H., Kashihara, M., Yamamoto, C., Sonoda, K., Okamoto, I., Nakagawa, K., Ohdo, S., Tanaka, Y., Kuwano, M. & Ono, M., May 1 2013, In : Cancer Science. 104, 5, p. 573-583 11 p.

Research output: Contribution to journal › Article

Sorting Nexins

Epidermal Growth Factor Receptor

Membranes

Pharmaceutical Preparations

Lung Neoplasms

2012

[Molecular-targeted drug for non-small cell lung cancer].

Okamoto, I., Jan 1 2012, In : Unknown Journal. 70 Suppl 8, p. 438-442 5 p.

Research output: Contribution to journal › Article

Fusion Oncogene Proteins

Anilides

Molecular Targeted Therapy

Pyrimidines

Non-Small Cell Lung Carcinoma

99 Citations (Scopus)

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer

Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., Kaneda, H., Takezawa, K., Kuwata, K., Yamaguchi, H., Hatashita, E., Nishio, K. & Nakagawa, K., Nov 15 2012, In : Clinical Cancer Research. 18, 22, p. 6219-6226 8 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Epidermal Growth Factor

Protein-Tyrosine Kinases

Lung Neoplasms

Epidermal Growth Factor Receptor

13 Citations (Scopus)

A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer

Sakai, K., Okamoto, I., Takezawa, K., Hirashima, T., Kaneda, H., Takeda, M., Matsumoto, K., Kimura, H., Fujita, Y., Nakagawa, K., Arao, T. & Nishio, K., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 5, p. 913-918 6 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Mass Spectrometry

Paraffin

Formaldehyde

Fluorescence In Situ Hybridization

58 Citations (Scopus)

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

Okamoto, W., Okamoto, I., Arao, T., Kuwata, K., Hatashita, E., Yamaguchi, H., Sakai, K., Yanagihara, K., Nishio, K. & Nakagawa, K., Jul 1 2012, In : Molecular Cancer Therapeutics. 11, 7, p. 1557-1564 8 p.

Research output: Contribution to journal › Article

Protein-Tyrosine Kinases

Stomach Neoplasms

X-Linked Inhibitor of Apoptosis Protein

Apoptosis

Inhibitor of Apoptosis Proteins

28 Citations (Scopus)

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment

Azuma, K., Okamoto, I., Kawahara, A., Taira, T., Nakashima, K., Hattori, S., Kinoshita, T., Takeda, M., Nakagawa, K., Takamori, S., Kuwano, M., Ono, M. & Kage, M., Jan 1 2012, In : Journal of Thoracic Oncology. 7, 1, p. 122-127 6 p.

Research output: Contribution to journal › Article

Epidermal Growth Factor Receptor

Non-Small Cell Lung Carcinoma

Disease-Free Survival

Mutation

Antibodies